Key Takeaways
Rare diseases aren’t actually rare in aggregate: collectively, they affect hundreds of millions of people worldwide, yet access to treatment for them lags far behind more common conditions. That gap exists because traditional pharmaceutical access models were built for volume, and rare diseases don’t work that way.
- Rare diseases affect more people than most assume, and traditional access models don’t fit rare disease realities.
- Effective access requires early, direct engagement with hospitals, providers, regulators, and payers.
- As more rare disease therapies enter the pipeline, access models have to shift from volume-based thinking to patient-centered design.
“Rare” can be misleading when it comes to rare disease. The term can evoke a handful of cases scattered around the world, or conditions so unusual that they barely register as a public health concern. The numbers tell a different story. According to Rare Diseases International, between 6,000 and 8,000 known rare diseases affect an estimated 300 million people globally, more than the population of the United States.
Yet the scale of the rare disease population does not translate into straightforward access to treatment. Traditional pharmaceutical access models were largely designed for markets with larger patient populations, predictable demand, and established pathways to registration, reimbursement, and distribution. Rare disease presents a very different set of challenges.
Several characteristics make access particularly complex:
- Small, dispersed patient populations: Individual rare diseases may affect only a small number of patients, often spread across multiple geographies and healthcare systems.
- High-cost, low-volume treatments with few or no alternatives: The economics of developing and delivering therapies for small patient populations can create significant challenges for pricing, reimbursement, and long-term sustainability.
- Complex registration, reimbursement, and distribution pathways: Local regulatory requirements, limited treatment infrastructure, and fragmented distribution networks can delay or restrict access even when a treatment is available elsewhere.
These factors can make conventional approaches difficult to apply. In rare disease, access often depends on creating more flexible pathways that account for the realities of small patient populations, complex healthcare systems, and treatments that may require highly specialized care.
The challenge is therefore not simply making a treatment available. It is building a pathway that can connect the right patient to the right treatment, in the right market, under the conditions that actually exist.
What It Actually Takes to Get Rare Disease Patients Treated
An effective rare disease access strategy must be built for complexity and sustainability from the start. That means:
- Enabling patients to access their full course of treatment, not just a few boxes.
- Collaborating directly with local hospitals and providers to navigate product registration and supply chain obstacles.
- Engaging regulators, payers, and distributors early to address requirements and ensure long-term access.
- Creating win-win solutions that meet the needs of all stakeholders, from pharmaceutical companies to patients and caregivers.
The Path Forward: Discovery Isn’t Enough Without Delivery
The rare disease pharmaceutical pipeline is only getting fuller, which makes the access question more urgent, not less. A therapy sitting in a lab or a warehouse doesn’t help anyone; what matters now is whether access models can catch up to what the science has already made possible. That shift, from optimizing for volume to designing around the patient, is what will determine whether these innovations actually reach the people they were built for.
Getting there takes a few concrete commitments:
- Prioritize patient need, not volume
- Design sustainable, flexible access pathways
- Anticipate local regulatory and supply chain barriers: Don’t wait to react, plan ahead.
- Make innovation accessible, no matter how rare the condition
Any single rare disease is uncommon by definition. Add them together, and they’re a significant global health challenge that access models have largely failed to treat as one. Getting this right was never just a business problem. What’s the purpose of a breakthrough that never makes it to the patient?
